13 results
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM ... #Honc #hemophilia ... VisualAbstract #NEJM
Evaluation of Lymphadenopathy - Localized vs Generalized #Diagnosis #EM #IM #Honc #Lymphadenopathy #Localized #Generalized #Infectious #Malignancy
Lymphadenopathy - Localized vs ... Generalized #Diagnosis #EM ... #IM #Honc #Lymphadenopathy
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
Major Clinical Trials and Evidence Summary for Transfusion Thresholds in Critical Care

TRICC - NEJM 1999 -
Care TRICC - NEJM ... 1999 - ICU FOCUS ... - NEJM 2011 - Hip ... UGIB TRISS - NEJM ... /vmoitra) #EBM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
PARAMEDIC2 Trial Visual Abstract: 
Adrenaline vs. Placebo in out-of-hospital
 - Tommaso Scquizzato
@tscquizzato

https://www.nejm.org/doi/full/10.1056/NEJMoa1806842
 A Randomized Trial of
: Adrenaline vs ... Cardiac Arrest #EBM ... #Prehospital #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
of Progression #EBM ... #Honc #MGUS #Progression ... MultipleMyeloma #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... VisualAbstract #NEJM
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma - Recurrence-free Survival in the
Intention-to-Treat Population #EBM ... #Honc #Nivolumab ... Ipilimumab #Melanoma #NEJM